62785-05-1

Usage

Chemical Structure

A triazine ring with two amine groups at positions 2 and 4, and two bromophenyl groups attached to the nitrogen atoms at positions 1 and 3, with a chlorine atom at position 6.

Usage

a. Building block in the synthesis of pharmaceuticals, agrochemicals, and dyes.
b. Potential applications in materials science and catalysis.
c. Investigated for its potential use in the treatment of various diseases, including cancer and parasitic infections.
d. Effective inhibitor of certain enzymes.
e. Studied for its potential use in the development of new antimicrobial agents.

Biological Activities

Diverse biological activities, including potential use in disease treatment and enzyme inhibition.

Industrial Applications

Used in the production of various industrial and consumer products.

Stability

Likely stable under normal temperature and pressure conditions.

Reactivity

May react with strong acids, bases, or oxidizing agents.

Solubility

Solubility in organic solvents, such as ethanol or dimethyl sulfoxide (DMSO), is possible.

Handling

Use gloves, eye protection, and a lab coat when handling 1,3,5-Triazine-2,4-diamine, N,N'-bis(4-bromophenyl)-6-chloro-.

Storage

Store in a cool, dry, and well-ventilated area, away from incompatible substances.

Disposal

Dispose of according to local regulations and safety guidelines.

Regulatory Information

May be subject to specific regulations depending on the intended use and location.

Upstream product

• 108-77-0 1,3,5-trichloro-2,4,6-triazine 
• 106-40-1 4-bromo-aniline 
• 20376-36-7 N-(4-bromophenyl)-4,6-dichloro-1,3,5-triazin-2-amine 

Downstream Products

• 1258254-42-0 C₂₄H₁₆Br₂N₈O₂S 
• 1450982-30-5 N²,N⁴-bis(4-bromophenyl)-6-(4-(2-((7-chloroquinolin-4-yl)amino)-ethyl)piperazin-1-yl)-1,3,5-triazine-2,4-diamine 
• 1453805-39-4 N²,N⁴-bis(4-bromophenyl)-6-(piperazin-1-yl)-1,3,5-triazine-2,4-diamine 
• 1453805-40-7 4-(4,6-bis(4-bromophenylamino)-1,3,5-triazin-2-yl)-N-(7-chloroquinolin-4-yl)piperazine-1-carbothioamide 
• 1408322-21-3 C₂₈H₂₄Br₂N₁₀S₂ 
• 84688-97-1 4-[4,6-Bis-(4-bromo-phenylamino)-[1,3,5]triazin-2-ylamino]-benzoic acid methyl ester 
• 84688-79-9 1-{4-[4,6-Bis-(4-bromo-phenylamino)-[1,3,5]triazin-2-ylamino]-phenyl}-ethanone 

Relevant academic research and scientific papers

Discovery of novel 1,3,5-triazine-thiazolidine-2,4-diones as dipeptidyl peptidase-4 inhibitors with antibacterial activity targeting the S1 pocket for the treatment of type 2 diabetes

A novel series of 1,3,5-triazine-thiazolidine-2,4-diones was synthesized and characterized by a number of analytical and spectroscopic techniques. The molecules were screened for the in vitro inhibition of dipeptidyl peptidase-4 and compound 7a showed the most prominent inhibition with IC50 = 6.25 μM. The other compounds showed considerable inhibition (IC50 = 12.11-49.21 μM). Docking studies indicated that the lipophilic thiazolidine-2,4-dione fragment of ligand 7a was oriented towards the tight lipophilic cavity of the S1 pocket of the active site formed by residues such as Tyr631, Val656, Trp659, Tyr662, Tyr666 and Val711 via the formation of H-bonds with Tyr547. One of the amines present on the wings of the triazine formed a hydrogen bond with Glu205, a vital residue for the N-terminal recognition site with an efficient CDOCKER interaction energy. In a bacterial inhibition study, the entire set of compounds showed excellent activity and, in some instances, were found to be equipotent to the cefixime used as a standard.

Antimalarial activity and docking studies of novel bi-functional hybrids derived from 4-aminoquinoline and 1,3,5-triazine against wild and mutant malaria parasites as pf-DHFR inhibitor

Bi-functional conjugates comprised of 4-aminoquinoline and 1,3,5-triazine were synthesized through facile synthetic routes. These compounds were rigorously screened for determination of their antimalarial activity against wild and mutant cultured Plasmodium falciparum. The results disclosed that the conjugates have considerable antimalarial activity against both wild and mutant parasites with marked variation on changing the pattern of substitutions. The observed activity profiles were additionally substantiated by docking studies on both wild and quadruple mutant P. falciparum dihydrofolate reductase thymidylate synthase (pf-DHFR-TS).

4-Aminoquinoline-1,3,5-triazine: Design, synthesis, in vitro antimalarial activity and docking studies

A series of hybrid 4-aminoquinoline 1,3,5-triazine derivatives was synthesized and their chemical structure were confirmed by 1H-NMR, 13C-NMR, FT-IR and mass spectrometric analyses. In vitro antimalarial activity of these compounds was evaluated against chloroquine-sensitive (3D-7) and chloroquine resistant (RKL-2) strains of P. falciparum. Results showed that all compounds had considerable antimalarial activity against both the strains and further docking studies were performed on both wild type (1J3I.pdb) and quadruple mutant (N51I, C59R, S108 N, I164L, 3QG2.pdb) pf-DHFR-TS to quantify the structural parameter necessary for the activity.

Design, Facile Synthesis, and Antibacterial Activity of Hybrid 1,3,4-thiadiazole-1,3,5-triazine Derivatives Tethered via -S- Bridge

Some hybrid 1,3,4-thiadiazole-1,3,5-triazine derivatives tethered via -S- bridge were synthesized and characterized with the aid of spectroscopic and elemental analysis. These hybrid conjugates were then investigated for their antibacterial activity against selected Gram-positive and Gram-negative bacteria. Excellent to moderate antibacterial activity was presented by the target compounds.

Synthesis and antibacterial evaluation of series of novel tri-substituted-s-triazine derivatives

Two novel series of s-triazine derivatives (6a-e and 7a-f) were synthesized with various aromatic and heterocyclic amines. The synthesized compounds were subsequently evaluated for their in vitro antibacterial activity against three gram-positive viz. Bacillus subtilis (NCIM- 2063), Bacillus cereus (NCIM-2156), Staphylococcus aureus (NCIM-2079) and gram-negative bacteria viz. Pseudomonas aeruginosa (NCIM-2036), Escherichia coli (NCIM-2065) and Klebseilla pneumoniae (NCIM-2706) by the broth dilution method as recommended by the National Committee for Clinical Laboratory Standards (NCCLS) using streptomycin as reference standard. Structures of the synthesized compounds were elucidated on the basis of elemental analyses and spectral data. Springer Science+Business Media, LLC 2010.

Triaminotriazine DNA helicase inhibitors with antibacterial activity

Screening of a chemical library in a DNA helicase assay involving the Pseudomonas aeruginosa DnaB helicase provided a triaminotriazine inhibitor with good antibacterial activity but associated cytotoxicity toward mammalian cells. Synthesis of analogs provided a few inhibitors that retained antibacterial activity and demonstrated a significant reduction in cytotoxicity. The impact of serum and initial investigations toward a mode of action highlight several features of this class of compounds as antibacterials.